Page last updated: 2024-08-16

rivastigmine and Psychotic Disorders

rivastigmine has been researched along with Psychotic Disorders in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (50.00)29.6817
2010's4 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Beireis, LA; Burgett, RN; Farley, TM1
Chang, HA; Hsu, CC; Kao, YC; Ku, SC; Tzeng, NS1
Osborn, GG; Saunders, AV1
Jayaram, MB; Kour, K; Singh, J1
Ballmaier, M; Casamenti, F; Mazzoncini, R; Pepeu, G; Scali, C; Spano, PF; Zoli, M1
Antonello, RM; Bava, A; Cazzato, G; Griggio, S; Moretti, R; Torre, P; Ukmar, M1
Diraoui, S; Jansen, PA; van Melick, EJ1
Luce, AK; McKeith, IG; Reading, PJ1

Reviews

2 review(s) available for rivastigmine and Psychotic Disorders

ArticleYear
Current treatments for patients with Alzheimer disease.
    The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:9 Suppl 8

    Topics: Aggression; Alzheimer Disease; Behavior Therapy; Cholinesterase Inhibitors; Depression; Excitatory Amino Acid Antagonists; Galantamine; Health Status; Humans; Memantine; Neuroprotective Agents; Parasympathomimetics; Phenylcarbamates; Psychomotor Agitation; Psychotherapy; Psychotic Disorders; Rivastigmine; Time Factors; United States; United States Food and Drug Administration

2010
Acetylcholinesterase inhibitors for schizophrenia.
    The Cochrane database of systematic reviews, 2012, Jan-18, Volume: 1

    Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Psychotic Disorders; Randomized Controlled Trials as Topic; Rivastigmine; Schizophrenia; Schizophrenic Psychology

2012

Trials

2 trial(s) available for rivastigmine and Psychotic Disorders

ArticleYear
Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study.
    International journal of clinical practice, 2004, Volume: 58, Issue:4

    Topics: Aged; Aged, 80 and over; Aspirin; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Drug Therapy, Combination; Female; Humans; Male; Nimodipine; Phenylcarbamates; Psychotic Disorders; Rivastigmine; Treatment Outcome; Vasodilator Agents

2004
Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.
    Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:6

    Topics: Aged; Carbamates; Caregivers; Cognition Disorders; Female; Follow-Up Studies; Hallucinations; Humans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Psychotic Disorders; Rivastigmine; Stress, Psychological; Treatment Outcome

2001

Other Studies

4 other study(ies) available for rivastigmine and Psychotic Disorders

ArticleYear
Acute treatment of psychotic symptoms in a newly diagnosed Lewy body dementia patient with an accelerated titration schedule of rivastigmine and de-escalation of antipsychotics.
    BMJ case reports, 2019, Sep-04, Volume: 12, Issue:9

    Topics: Aged; Antipsychotic Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Hallucinations; Humans; Lewy Body Disease; Male; Psychotic Disorders; Quetiapine Fumarate; Rivastigmine

2019
Psychotic episode in a patient with Alzheimer's dementia while shifting from the oral to patch form of rivastigmine.
    The Journal of neuropsychiatry and clinical neurosciences, 2014,Summer, Volume: 26, Issue:3

    Topics: Administration, Cutaneous; Administration, Oral; Aged; Dementia; Humans; Male; Phenylcarbamates; Psychotic Disorders; Rivastigmine

2014
Rivastigmine antagonizes deficits in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis.
    Neuroscience, 2002, Volume: 114, Issue:1

    Topics: Acetylcholine; Acetylcholinesterase; Animals; Antibodies, Monoclonal; Basal Nucleus of Meynert; Carbamates; Cerebral Cortex; Choline O-Acetyltransferase; Cholinergic Fibers; Cholinesterase Inhibitors; Disease Models, Animal; Immunohistochemistry; Immunotoxins; Male; N-Glycosyl Hydrolases; Neural Inhibition; Neural Pathways; Neurons; Phenylcarbamates; Psychotic Disorders; Rats; Rats, Sprague-Dawley; Reflex, Startle; Ribosome Inactivating Proteins, Type 1; Rivastigmine; Saporins; Treatment Outcome

2002
[Clozapine for the treatment of psychosis in 3 elderly patients with Parkinson's disease].
    Nederlands tijdschrift voor geneeskunde, 2004, Nov-27, Volume: 148, Issue:48

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Male; Neuroprotective Agents; Olanzapine; Parkinson Disease; Phenylcarbamates; Psychotic Disorders; Rivastigmine; Treatment Outcome

2004